Thursday, October 30, 2025

Bridging the Gap: Perioperative Medicine for the Medical Consultant

Dr Neeraj Manikath , claude,ai

Abstract

Perioperative medical consultation represents a critical intersection between surgical and medical expertise, requiring nuanced decision-making that balances surgical necessity against medical risk. This review provides evidence-based guidance for critical care physicians and medical consultants managing common perioperative challenges, with emphasis on practical application of risk stratification tools, anticoagulation management, glycemic control, and post-operative complications. We present contemporary approaches to cardiac risk assessment, anticoagulation bridging, diabetic management, and common post-operative consultations including delirium, acute kidney injury, and atrial fibrillation.

Introduction

The perioperative period extends from the decision for surgery through complete recovery, representing a vulnerable window where physiologic stress unmasks underlying medical conditions. Medical consultants serve not merely as "clearance" providers but as partners in surgical decision-making, risk mitigation, and post-operative management. With approximately 300 million surgical procedures performed globally each year, and post-operative complications occurring in 3-17% of cases, the medical consultant's role has never been more critical.1

Cardiac Risk Stratification (NSQIP, RCRI) and When to Stress Test

Risk Assessment Tools

The Revised Cardiac Risk Index (RCRI), developed by Lee et al. in 1999, remains the most widely validated tool for predicting major cardiac complications (myocardial infarction, pulmonary edema, ventricular fibrillation, cardiac arrest, or complete heart block) after non-cardiac surgery.2 The RCRI assigns one point for each of six predictors:

High-risk surgery (intraperitoneal, intrathoracic, or suprainguinal vascular)
History of ischemic heart disease
History of congestive heart failure
History of cerebrovascular disease
Diabetes requiring insulin therapy
Preoperative creatinine >2 mg/dL

Cardiac event rates correlate with RCRI scores: Class I (0 points, 0.4%), Class II (1 point, 1.0%), Class III (2 points, 2.4%), and Class IV (≥3 points, 5.4%).2

The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) calculator provides a more comprehensive, procedure-specific risk prediction incorporating 21 patient variables including functional status, ASA class, and laboratory values. The NSQIP calculator demonstrates superior discrimination (C-statistic 0.944) compared to RCRI (0.672) for cardiac complications, though it requires online access and more data input.3

When to Order Stress Testing

Pearl: Most patients do NOT require pre-operative stress testing. The 2014 ACC/AHA guidelines recommend against routine testing in asymptomatic patients undergoing low- or intermediate-risk surgery, regardless of RCRI score.4

Consider stress testing only when:

The patient has poor or unknown functional capacity (<4 METs)
The procedure is high-risk (vascular surgery)
Results will change management (revascularization or surgery cancellation)

Hack: Use the "4-MET rule" for functional capacity assessment. If patients can climb two flights of stairs, perform heavy housework, or play tennis, they have adequate functional capacity (≥4 METs) and rarely require stress testing.4

Oyster: The CARP (Coronary Artery Revascularization Prophylaxis) trial demonstrated that prophylactic coronary revascularization before vascular surgery did not reduce perioperative mortality or myocardial infarction rates in stable coronary disease patients.5 Stress testing that leads to unnecessary revascularization may delay surgery without improving outcomes.

Beta-Blockade Considerations

The POISE trial's cautionary findings—increased mortality and stroke with perioperative beta-blockade initiation—shifted practice patterns dramatically.6 Current recommendations: continue beta-blockers in patients already taking them, but avoid initiating high-dose beta-blockers immediately preoperatively. If indicated, start at least 2-4 weeks before surgery with careful titration.

To Bridge or Not to Bridge? Managing Anticoagulation Perioperatively

The Bridging Paradigm Shift

The landmark BRIDGE trial (2015) fundamentally changed perioperative anticoagulation management, demonstrating that bridging anticoagulation with LMWH in patients with atrial fibrillation was associated with increased bleeding risk without reducing thromboembolic events.7

Key findings: Among patients with atrial fibrillation (97% with CHA₂DS₂-VASc ≥3), forgoing bridging resulted in 0.4% arterial thromboembolism versus 0.3% with bridging (non-inferior), while major bleeding occurred in 1.3% versus 3.2% (p<0.001).7

Risk-Stratified Approach

HIGH thrombotic risk (consider bridging):

Mechanical mitral valve
Older mechanical aortic valve (caged-ball, tilting disk)
Stroke/TIA within 3 months
Atrial fibrillation with CHA₂DS₂-VASc ≥7 plus prior stroke
VTE within 3 months

MODERATE risk (individualize, generally no bridging):

Bileaflet mechanical aortic valve with atrial fibrillation
VTE within 3-12 months
Severe thrombophilia (protein C/S deficiency, antiphospholipid syndrome)

LOW risk (no bridging):

Atrial fibrillation without mechanical valve (regardless of CHA₂DS₂-VASc)
Bileaflet mechanical aortic valve without additional risk factors
Remote VTE (>12 months) without recurrence

Practical Management Protocol

For warfarin:

Stop 5 days before surgery (INR typically <1.5 by surgery day)
If bridging indicated: start LMWH (enoxaparin 1 mg/kg BID) 3 days before surgery
Last LMWH dose 24 hours before surgery
Resume warfarin evening of surgery (if hemostasis adequate)
Resume therapeutic LMWH 24 hours post-op (48-72 hours for high bleeding-risk procedures)

Pearl: Check INR the day before surgery. If INR >1.5, consider low-dose vitamin K (1-2 mg PO).

Hack for DOACs: These have shorter half-lives, simplifying management. Stop apixaban/rivaroxaban 2-3 days before surgery (4-5 days for high bleeding-risk); dabigatran 3-5 days before (longer if CrCl <50). No bridging needed. Resume 2-3 days post-operatively.8

The Diabetic Surgical Patient: Managing Insulin and Oral Hypoglycemics

Preoperative Glycemic Targets

While tight perioperative glucose control intuitively seems beneficial, the evidence is nuanced. Target glucose 80-180 mg/dL perioperatively, avoiding both hyperglycemia (>180 mg/dL, associated with infection risk) and hypoglycemia (<70 mg/dL, associated with mortality).9

Oyster: The NICE-SUGAR trial demonstrated increased mortality with intensive glucose control (81-108 mg/dL) versus conventional control (≤180 mg/dL) in critically ill patients.10 Perioperative patients are similarly vulnerable to hypoglycemia.

Morning-of-Surgery Medication Management

Oral hypoglycemics:

Metformin: Hold on surgery day; resume when eating and eGFR stable (concern for lactic acidosis with contrast or hemodynamic instability)
Sulfonylureas: Hold 24 hours before surgery (risk of hypoglycemia while NPO)
DPP-4 inhibitors: Continue (low hypoglycemia risk, beneficial in hospital setting)
SGLT-2 inhibitors: Hold 3-4 days before major surgery (euglycemic DKA risk, volume depletion)
GLP-1 agonists: Hold on surgery day (delayed gastric emptying, aspiration risk)

Insulin regimens:

Type 1 diabetes or insulin-dependent Type 2:

Give 50-80% of basal insulin (NPH, glargine, degludec) on surgery morning
Hold short-acting/mealtime insulin
Initiate dextrose-containing IV fluids
Check glucose every 1-2 hours

Pearl: NEVER completely withhold basal insulin in Type 1 diabetes—this invites DKA.

Non-insulin-dependent Type 2 diabetes:

Hold all insulin on surgery morning
Monitor glucose every 2 hours
Use correction-dose rapid-acting insulin for glucose >180 mg/dL

Intraoperative and Postoperative Management

For prolonged procedures or unstable patients, insulin infusion protocols provide superior control. The Portland Protocol and Yale Protocol are well-validated approaches achieving target glucose 100-140 mg/dL.11

Hack: The "Rule of 1800" estimates insulin sensitivity: 1800 ÷ total daily insulin dose = drop in glucose (mg/dL) per 1 unit rapid-acting insulin. Example: patient takes 60 units daily; 1800 ÷ 60 = 30 mg/dL drop per unit.

Transition to subcutaneous insulin when eating resumes, using basal-bolus regimen rather than sliding-scale monotherapy (associated with worse outcomes).12

Post-Op Fever: The 5 W's

The classic mnemonic "5 W's" provides a temporal framework for post-operative fever evaluation:

Wind (POD 0-2): Atelectasis/Pneumonia

Most common early fever cause
Incentive spirometry, early mobilization preventive
Pneumonia typically after 48 hours
Oyster: Fever from atelectasis alone is controversial; search for alternative causes

Water (POD 3-5): Urinary Tract Infection

Risk factors: prolonged catheterization, female sex, instrumentation
Remove urinary catheters early (each day increases infection 3-7%)
Pearl: Asymptomatic bacteriuria doesn't require treatment; treat only symptomatic UTI

Wound (POD 5-7): Surgical Site Infection

Erythema, warmth, purulent drainage, dehiscence
Staphylococcus aureus and Streptococcus most common
Deep infections may present later (7-30 days)

Walking (POD 5-14): Venous Thromboembolism

DVT/PE presents with asymmetric leg swelling, tachycardia, hypoxia
Prophylaxis essential: pharmacologic plus sequential compression devices
Hack: Wells' score helps estimate PE probability; D-dimer useful only if low pretest probability

Wonder Drugs (POD 0-any): Drug Fever

Antibiotics (especially beta-lactams), antiepileptics, allopurinol common culprits
Diagnosis of exclusion after ruling out infections
Typically occurs 7-10 days after drug initiation
Fever resolves 2-3 days after discontinuation

Additional Considerations

POD 0-1: Malignant hyperthermia (rare, genetic; treat with dantrolene), transfusion reactions

POD 7+: Clostridium difficile infection (antibiotic-associated), intra-abdominal abscess, anastomotic leak

Pearl: Not all post-operative fevers require antibiotics. Transient temperature elevation in first 48 hours is often inflammatory response to surgery. Investigate, but don't reflexively treat.

Common Post-Op Consults: Delirium, AKI, and Atrial Fibrillation

Post-Operative Delirium

Delirium affects 15-50% of post-operative patients, increasing mortality, hospital length-of-stay, and long-term cognitive decline.13

Risk factors: Age >70, baseline cognitive impairment, sensory impairment, dehydration, polypharmacy, sleep deprivation, pain, immobilization

Assessment: CAM-ICU or CAM (Confusion Assessment Method) screens for:

Acute onset and fluctuating course
Inattention
Disorganized thinking OR altered consciousness

Management—the ABCDEF bundle:

Assess, prevent, manage pain (opioid-sparing strategies)
Both SAT and SBT (spontaneous awakening/breathing trials if ventilated)
Choice of sedation (avoid benzodiazepines; prefer dexmedetomidine if needed)
Delirium assessment (routine screening)
Early mobility (physical therapy, walking)
Family engagement (reorientation, familiar objects)

Pearl: Treat underlying causes—hypoxia, infection, metabolic derangements, urinary retention. Avoid restraints when possible.

Oyster: Antipsychotics (haloperidol, quetiapine) don't prevent delirium and may not reduce duration, but can manage severe agitation threatening patient/staff safety.14 Use sparingly, lowest effective dose.

Hack: The "DELIRIUM" mnemonic for causes:

Drugs (anticholinergics, benzodiazepines, opioids)
Electrolyte disturbances
Lack of drugs (withdrawal)
Infection
Reduced sensory input (glasses, hearing aids)
Intracranial (stroke, bleed)
Urinary retention/fecal impaction
Myocardial (MI, CHF, arrhythmia)

Acute Kidney Injury

Post-operative AKI occurs in 1-25% depending on surgery type, dramatically increasing mortality.15

KDIGO classification (creatinine rise or urine output):

Stage 1: 1.5-1.9× baseline or ≥0.3 mg/dL increase
Stage 2: 2-2.9× baseline
Stage 3: ≥3× baseline or initiation of RRT

Differential diagnosis:

Prerenal (most common): Hypovolemia, hemorrhage, hypotension, cardiorenal syndrome
Intrinsic renal: ATN (prolonged prerenal state), contrast nephropathy, rhabdomyolysis, interstitial nephritis
Postrenal: Obstruction (rare post-operatively unless urologic surgery)

Management approach:

Stop nephrotoxins: NSAIDs, aminoglycosides, vancomycin (adjust dosing), contrast
Optimize volume status: Fluid resuscitation if hypovolemic; diuresis if hypervolemic
Correct electrolyte abnormalities: Hyperkalemia, acidosis
Adjust medication dosing: Renally-cleared drugs
Urinalysis and microscopy: Distinguish ATN (muddy brown casts) from other etiologies

Pearl: FENa <1% suggests prerenal etiology in absence of diuretics; FEUrea <35% more reliable with diuretics.

Oyster: "Renal dose dopamine" doesn't prevent AKI or improve outcomes—this practice should be abandoned.16

Hack: Fluid balance matters. The RELIEF trial showed restrictive fluid strategies reduced AKI risk compared to liberal approaches in major abdominal surgery.17 Avoid fluid overload while maintaining adequate perfusion.

Post-Operative Atrial Fibrillation

POAF occurs in 20-50% of cardiac surgeries and 5-10% of non-cardiac thoracic surgeries, typically POD 2-4.18

Pathophysiology: Inflammation, sympathetic activation, atrial stretch, electrolyte shifts, hypoxia

Management priorities:

Identify and treat triggers: Hypoxia, pain, infection, electrolyte abnormalities (especially hypomagnesemia, hypokalemia)
Rate control (first-line):
- Beta-blockers: Metoprolol 5 mg IV or 25-50 mg PO
- Calcium channel blockers: Diltiazem 0.25 mg/kg IV bolus, then infusion
- Avoid in hypotension or decompensated CHF
Rhythm control (selective cases):
- Amiodarone if hemodynamically unstable or CHF present
- Electrical cardioversion if hemodynamically compromised
Anticoagulation:
- CHA₂DS₂-VASc score guides decision
- Balance thrombotic risk against post-operative bleeding risk
- Generally start if POAF persists >48 hours and CHA₂DS₂-VASc ≥2

Pearl: Correct magnesium to >2 mg/dL and potassium to >4 mEq/L—this alone may restore sinus rhythm.

Oyster: Most POAF (80-90%) converts spontaneously within 24-48 hours. Don't rush to aggressive rhythm control unless hemodynamically unstable.

Hack: Prophylactic beta-blockers reduce POAF incidence by 30% in cardiac surgery patients—consider continuing home beta-blockers perioperatively.19

Conclusion

Effective perioperative medical consultation requires synthesis of risk stratification, evidence-based medication management, and prompt recognition of post-operative complications. The consultant's role extends beyond preoperative "clearance" to active participation in risk modification, surgical timing decisions, and post-operative management. By applying validated tools like RCRI and NSQIP, adhering to contemporary anticoagulation bridging evidence, optimizing glycemic control, and systematically approaching common complications, medical consultants can substantially improve surgical outcomes. As perioperative medicine evolves toward collaborative, multidisciplinary models, the medical consultant remains indispensable in navigating the complex intersection of surgical necessity and medical optimization.

References

Weiser TG, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372(9633):139-144.
Lee TH, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043-1049.
Bilimoria KY, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator. Br J Surg. 2013;100(11):1466-1473.
Fleisher LA, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2014;130(24):e278-e333.
McFalls EO, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351(27):2795-2804.
Devereaux PJ, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet. 2008;371(9627):1839-1847.
Douketis JD, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823-833.
Doherty JU, et al. 2017 ACC Expert Consensus Decision Pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2017;69(7):871-898.
Duggan EW, et al. Perioperative hyperglycemia management: an update. Anesthesiology. 2017;126(3):547-560.
NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297.
Goldberg PA, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004;27(2):461-467.
Umpierrez GE, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181-2186.
Inouye SK, et al. Delirium in elderly people. Lancet. 2014;383(9920):911-922.
Girard TD, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506-2516.
O'Connor ME, et al. Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg. 2017;104(7):868-876.
Bellomo R, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000;356(9248):2139-2143.
Myles PS, et al. Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018;378(24):2263-2274.
Mathew JP, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291(14):1720-1729.
Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004;(4):CD003611.

Word Count: 2,847 words

Disclosure: No conflicts of interest to declare.

The Liver in Trouble: A Guide to Acute Liver Failure and Decompensated Cirrhosis

Dr Neeraj Manikath , claude.ai

Introduction

The critically ill patient with hepatic dysfunction represents one of the most challenging scenarios in intensive care medicine. Whether confronting the catastrophic presentation of acute liver failure (ALF) or managing the complex cascade of decompensated cirrhosis, intensivists must navigate a labyrinth of pathophysiological derangements, competing management priorities, and time-sensitive decisions. This review provides a practical, evidence-based approach to these conditions, emphasizing recent advances and clinical pearls that can improve outcomes in this vulnerable population.

Acute Liver Failure: The Acetaminophen vs. Non-Acetaminophen Divide

Acute liver failure, defined as the development of coagulopathy (INR ≥1.5) and any degree of encephalopathy in a patient without pre-existing liver disease and with illness duration <26 weeks, remains a medical emergency with mortality approaching 40% without liver transplantation.[1] The etiology fundamentally shapes prognosis, management, and transplant candidacy, making the acetaminophen versus non-acetaminophen distinction clinically crucial.

Acetaminophen-Induced ALF: The Good News Story

Acetaminophen toxicity accounts for approximately 46% of ALF cases in the United States and paradoxically carries the best spontaneous survival rate (approximately 65%).[2] The key to management lies in early recognition and aggressive N-acetylcysteine (NAC) administration.

Pearl: NAC should be initiated in any patient with acetaminophen ingestion meeting treatment criteria (Rumack-Matthew nomogram for acute ingestions) or with ALF of uncertain etiology. The beneficial effects extend beyond glutathione repletion and include improved microcirculatory function, reduced oxidative stress, and immunomodulatory effects.[3]

Hack: In established ALF, continue NAC until INR <2.0, regardless of time since ingestion. The traditional 72-hour protocol is inadequate in severe hepatotoxicity. Use the standard three-bag protocol or, increasingly popular in many centers, the two-bag protocol (200 mg/kg over 4 hours, then 100 mg/kg over 16 hours) which demonstrates equivalent efficacy with fewer anaphylactoid reactions.[4]

Oyster: Extremely elevated transaminases (AST/ALT >10,000 IU/L) with rapidly improving values paradoxically suggest better prognosis in acetaminophen toxicity—it reflects acute necrosis with potential for regeneration. Persistent elevation with worsening synthetic function portends poor outcomes.

Non-Acetaminophen ALF: The Challenging Cases

Non-acetaminophen etiologies include viral hepatitis (particularly hepatitis A, B, and E), autoimmune hepatitis, drug-induced liver injury (DILI), Wilson's disease, Budd-Chiari syndrome, acute fatty liver of pregnancy, and indeterminate causes (15-20% of cases).[1] These carry worse spontaneous survival rates (25-40%) and require careful evaluation for transplant candidacy.

Pearl: In idiosyncratic DILI, which may present weeks after drug initiation, NAC administration shows mortality benefit despite different pathophysiology. The US Acute Liver Failure Study Group demonstrated improved transplant-free survival in non-acetaminophen ALF patients receiving NAC.[5]

Critical Distinction: Apply King's College Criteria for transplant evaluation, recognizing their etiology-specific performance. For acetaminophen-induced ALF: arterial pH <7.3 after resuscitation OR INR >6.5, creatinine >3.4 mg/dL, and grade III-IV encephalopathy. For non-acetaminophen ALF: INR >6.5 alone OR any three of five criteria (age >40 or <10 years, non-A/non-B hepatitis, halothane hepatitis, drug reaction, jaundice >7 days before encephalopathy, INR >3.5, bilirubin >17.5 mg/dL).[6]

The Cirrhotic Patient: Understanding the Precipitants of Decompensation

Cirrhosis affects approximately 4.5 million Americans, with decompensation marking a critical transition from compensated disease (median survival >12 years) to decompensated disease (median survival ~2 years).[7] Understanding and addressing precipitants represents the cornerstone of ICU management.

Common Precipitants: The "Big Five"

Infection (most common, 30-50% of cases): Bacterial infections, particularly SBP, urinary tract infections, and pneumonia, trigger inflammatory cascades that worsen portal hypertension and organ dysfunction. Pearl: Maintain high suspicion—cirrhotic patients may not mount typical inflammatory responses (fever, leukocytosis).
Gastrointestinal bleeding: Variceal hemorrhage increases portal pressure, delivers nitrogenous load to the colon (precipitating encephalopathy), and causes hemodynamic instability. Hack: Target hemoglobin 7-9 g/dL in variceal bleeding—liberal transfusion increases portal pressure and rebleeding risk.[8]
Medications and toxins: NSAIDs cause renal impairment and fluid retention; sedatives precipitate encephalopathy; nephrotoxic agents trigger hepatorenal syndrome. Pearl: Review all medications, including over-the-counter and herbal supplements—many contain hidden hepatotoxins.
Portal vein thrombosis: Occurs in 10-25% of cirrhotic patients, particularly with hepatocellular carcinoma. Oyster: Elevated D-dimer in cirrhosis doesn't rule out thrombosis—these patients have complex coagulopathy with both pro-thrombotic and anti-thrombotic derangements.
Non-compliance: Dietary indiscretion (sodium/fluid intake) or medication non-adherence frequently precipitate decompensation in otherwise stable patients.

Acute-on-Chronic Liver Failure (ACLF): The New Paradigm

ACLF represents acute deterioration of liver function with organ failure(s) in patients with cirrhosis, carrying 28-day mortality of 15-75% depending on severity.[9] The CLIF-C ACLF score (incorporating organ failures) provides superior prognostication compared to traditional Child-Pugh or MELD scores. Critical pearl: Early identification and aggressive treatment of precipitants may reverse ACLF, but persistent multi-organ failure warrants transplant evaluation or palliative care discussions.

Managing Ascites and Spontaneous Bacterial Peritonitis (SBP)

Ascites develops in 60% of cirrhotic patients within 10 years of diagnosis, marking transition to decompensation and conferring 40% two-year mortality.[10]

Ascites Management: Beyond Diuretics

First-line therapy combines sodium restriction (2 g/day) with diuretics: spironolactone 100 mg plus furosemide 40 mg, maintaining the 100:40 ratio during uptitration (maximum 400:160 mg). This ratio prevents hypokalemia and achieves effective natriuresis in 90% of patients.[11]

Pearl: Perform diagnostic paracentesis in ALL patients with new-onset ascites and ANY cirrhotic patient with ascites admitted to hospital. The procedure has <1% complication rate and provides critical diagnostic information.

Hack for refractory ascites: Large-volume paracentesis (LVP) with albumin replacement (8 g per liter removed for >5L) proves safer and more effective than aggressive diuretic escalation. Post-paracentesis circulatory dysfunction occurs in 70% without albumin but only 20% with albumin replacement, translating to improved survival.[12]

Oyster: The serum-ascites albumin gradient (SAAG) ≥1.1 g/dL indicates portal hypertension with 97% accuracy, regardless of infection or malignancy. Don't be misled by infected or bloody ascites—SAAG remains interpretable.

SBP: Diagnosis and Management

SBP occurs in 10-30% of hospitalized cirrhotic patients with ascites and carries mortality of 20-40% despite appropriate antibiotics.[13] Diagnosis requires ascitic fluid polymorphonuclear cell count ≥250 cells/mm³.

Critical pearls for SBP management:

Start antibiotics immediately upon diagnostic suspicion—don't wait for culture results. Third-generation cephalosporins (cefotaxime 2g IV q8h or ceftriaxone 2g IV daily) remain first-line therapy. In areas with high fluoroquinolone resistance or in patients on quinolone prophylaxis, consider piperacillin-tazobactam or carbapenems.
Give intravenous albumin (1.5 g/kg at diagnosis, 1 g/kg on day 3) to ALL patients with SBP and creatinine >1 mg/dL, BUN >30 mg/dL, or total bilirubin >4 mg/dL. This intervention reduces hepatorenal syndrome incidence from 33% to 10% and improves survival from 71% to 90%.[14]
Repeat paracentesis at 48 hours to document response (>25% decrease in PMN count). Non-response suggests resistant organisms or secondary peritonitis.

Hack: Secondary bacterial peritonitis (bowel perforation) should be suspected with ascitic fluid showing: protein >1 g/dL, glucose <50 mg/dL, LDH greater than serum upper limit of normal, or polymicrobial culture. These patients need surgical evaluation, not just antibiotics.

Hepatic Encephalopathy: From Lactulose to Rifaximin

Hepatic encephalopathy (HE) occurs in 30-45% of cirrhotic patients and significantly impairs quality of life while increasing mortality risk.[15] Understanding the ammonia-centric but multifactorial pathophysiology guides rational therapy.

Grading and Recognition

West Haven criteria remain standard: Grade 0 (minimal/covert HE detectable only by psychometric testing), Grade 1 (mild confusion, altered sleep), Grade 2 (lethargy, disorientation), Grade 3 (somnolent but rousable, marked confusion), Grade 4 (coma). Pearl: Covert HE affects 30-80% of cirrhotic patients and impairs driving safety and work performance—consider screening all cirrhotic patients.

Management: The Stepwise Approach

Step 1: Lactulose remains first-line therapy despite limited high-quality evidence. Target 2-3 soft bowel movements daily, typically requiring 15-30 mL orally 2-4 times daily. Mechanism involves acidification of colonic contents (reducing ammonia absorption), cathartic effects (reducing ammonia-producing bacteria), and potential prebiotic effects.[16]

Hack: In severe HE, administer lactulose via nasogastric tube or rectal enema (300 mL lactulose in 700 mL water, retain 30-60 minutes). Don't hold lactulose for "diarrhea"—that's the therapeutic goal.

Oyster: Lactulose should NOT be administered to patients with suspected bowel obstruction or perforation. Overzealous lactulose causing severe diarrhea, dehydration, and hypernatremia may paradoxically worsen HE and precipitate hepatorenal syndrome.

Step 2: Rifaximin (550 mg PO BID), a minimally absorbed antibiotic targeting ammonia-producing gut bacteria, added to lactulose reduces HE episodes by 50% compared to lactulose alone and decreases hospitalization rates.[17] Cost remains prohibitive in some settings, but benefits justify use in recurrent HE.

Step 3: Adjunctive therapies include zinc supplementation (particularly if deficient), L-ornithine L-aspartate (LOLA, more commonly used in Europe), and polyethylene glycol (3.5-day course shows equal efficacy to lactulose for acute HE with faster resolution).[18]

Critical management points:

Search for precipitants aggressively: infection, GI bleeding, constipation, medications (especially sedatives, narcotics), hypokalemia, azotemia, TIPS dysfunction.
Minimize sedation: If intubation required (Grade 4 HE), use propofol or dexmedetomidine rather than benzodiazepines.
Protein restriction is obsolete: Maintain 1.2-1.5 g/kg/day protein intake. Vegetable and dairy proteins may be better tolerated than meat proteins.

Pearl: Ammonia levels correlate poorly with HE severity and should NOT guide treatment decisions. Use clinical assessment and don't wait for ammonia results to initiate therapy.

The Hepatorenal Syndrome: Diagnosis and the Role of Vasoconstrictors

Hepatorenal syndrome (HRS) represents functional renal failure in advanced liver disease, occurring in 20-40% of cirrhotic patients and carrying 50% two-week mortality without treatment.[19] The 2019 International Club of Ascites redefined HRS as a continuum: HRS-acute kidney injury (HRS-AKI) replacing the old HRS type 1, and HRS-non-AKI (formerly HRS type 2).

Diagnostic Criteria: The Updated Approach

HRS-AKI diagnosis requires cirrhosis with ascites, AKI according to ICA-AKI criteria (increase in serum creatinine ≥0.3 mg/dL within 48 hours or ≥50% increase from baseline within 7 days), absence of response to diuretic withdrawal and volume expansion with albumin (1 g/kg/day for 2 days, maximum 100 g/day), absence of shock, no current or recent nephrotoxic drugs, and no proteinuria (<500 mg/day) or microhematuria (<50 RBCs/high-power field) or abnormal renal ultrasound.[20]

Pearl: "Renal failure in a patient with liver failure" encompasses many diagnoses—prerenal azotemia, acute tubular necrosis, HRS, and glomerulonephritis. Systematically exclude alternatives before diagnosing HRS. Fractional excretion of sodium <1% suggests functional renal failure but doesn't distinguish prerenal azotemia from HRS.

Pathophysiology: The Vascular Hypothesis

HRS results from extreme splanchnic vasodilation with "effective" arterial hypovolemia, triggering neurohormonal activation (RAAS, sympathetic nervous system, vasopressin) causing intense renal vasoconstriction. This explains why crystalloid administration worsens outcomes while albumin and vasoconstrictors help.

Vasoconstrictor Therapy: The Game Changer

Vasoconstrictor therapy aims to increase effective arterial blood volume by splanchnic vasoconstriction, improving renal perfusion. Multiple randomized trials demonstrate HRS reversal in 30-50% of patients treated with vasoconstrictors plus albumin versus 10% with albumin alone.[21]

Agent Selection:

Terlipressin (0.5-2 mg IV q4-6h, titrated to increase MAP by 15 mmHg or creatinine decrease): The only FDA-approved therapy for HRS-AKI (approved 2022), showing significant HRS reversal in the CONFIRM trial. Superior efficacy to alternatives but associated with ischemic complications in 5-10% (particularly respiratory failure, need continuous monitoring).[22]
Norepinephrine (0.5-3 mg/hour continuous infusion): Cheaper alternative showing comparable efficacy to terlipressin in meta-analyses but requiring ICU monitoring for continuous infusion. Hack: Some centers use this as first-line in ICU patients already requiring hemodynamic monitoring.
Midodrine plus octreotide (midodrine 7.5-15 mg PO TID plus octreotide 100-200 mcg SC TID): Oral/subcutaneous option for non-ICU patients, though less effective than terlipressin. Useful for HRS-non-AKI or step-down therapy.

Critical management protocol:

Start albumin concomitantly: 1 g/kg day 1 (maximum 100 g), then 20-40 g/day. Albumin expands plasma volume, has immunomodulatory effects, and improves outcomes independently.
Monitor closely: Daily creatinine, urine output, volume status. Expect response within 3-5 days. Continue therapy until creatinine <1.5 mg/dL or for 14 days maximum.
Watch for ischemic complications: Particularly with terlipressin—abdominal pain, diarrhea, skin mottling, digital ischemia, and myocardial ischemia occur in 5-10%. Hold therapy if complications develop.

Oyster: HRS reversal with medical therapy serves as a bridge to transplantation, not definitive cure. Recurrence occurs in 20% within 30 days. Without transplantation, median survival remains only 3-6 months even with treatment response.

Renal Replacement Therapy (RRT): Reserve for volume overload, severe hyperkalemia, or uremic complications. RRT doesn't improve HRS survival without transplant but serves as bridge for transplant candidates. Use continuous RRT (CRRT) for hemodynamically unstable patients. Pearl: Avoid ultrafiltration until MAP improves with vasoconstrictors—aggressive fluid removal worsens systemic hemodynamics in HRS.

Conclusion

Management of acute liver failure and decompensated cirrhosis demands systematic evaluation, early recognition of complications, aggressive treatment of precipitants, and thoughtful allocation of advanced therapies. The acetaminophen versus non-acetaminophen distinction fundamentally shapes ALF prognosis and NAC use. In cirrhosis, identifying decompensation triggers, evidence-based management of ascites and SBP with appropriate albumin use, rational HE therapy with lactulose and rifaximin, and early vasoconstrictor therapy for HRS improve outcomes. As medical therapies advance—from novel ammonia-lowering agents to improved vasoconstrictors—the intensivist's role in stabilizing these critically ill patients while facilitating timely transplant evaluation remains paramount. Recognition of futility in appropriate cases, with transition to palliative care, represents equally important expertise. The liver in trouble demands our best clinical judgment, combining evidence-based protocols with individualized care.

References

Lee WM, et al. Acute liver failure: Summary of a workshop. Hepatology. 2008;47(4):1401-1415.
Bernal W, et al. Acute liver failure. Lancet. 2010;376(9736):190-201.
Mumtaz K, et al. Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a liver transplant centre. QJM. 2009;102(7):493-497.
Bateman DN, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383(9918):697-704.
Lee WM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864.
O'Grady JG, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.
D'Amico G, et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231.
Villanueva C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21.
Moreau R, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.
Planas R, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385-1394.
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107.
Bernardi M, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181.
Fernández J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140-148.
Sort P, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409.
Bajaj JS, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646-1653.
Als-Nielsen B, et al. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.
Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
Rahimi RS, et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727-1733.
Gines P, et al. Hepatorenal syndrome. Lancet. 2003;362(9398):1819-1827.
Angeli P, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974.
Gluud LL, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576-584.
Wong F, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828.

The Hypertensive Emergency: Untangling Urgency from Emergency

A Critical Care Perspective on Blood Pressure Management

Dr Neeraj Manikath , claude.ai

Abstract

Distinguishing between hypertensive urgency and emergency remains a critical clinical challenge that dictates divergent management strategies. While both present with severely elevated blood pressure (typically ≥180/120 mmHg), only hypertensive emergency involves acute, progressive target organ damage requiring immediate parenteral therapy. This review elucidates the pathophysiology of target organ injury, evaluates first-line pharmacologic agents, addresses the risks of precipitous blood pressure reduction, and provides evidence-based approaches to special clinical scenarios. Recognizing that most patients presenting with severe hypertension do not require ICU admission and that aggressive treatment may cause harm represents a paradigm shift essential for contemporary critical care practice.

Introduction

Approximately 1-2% of patients with hypertension will experience a hypertensive crisis during their lifetime, yet only a fraction of these represent true emergencies.(1) The distinction between urgency and emergency hinges not on blood pressure values alone but on the presence or absence of acute end-organ damage. This fundamental principle prevents both undertreatment of life-threatening conditions and overtreatment of asymptomatic hypertension—a surprisingly common error that can precipitate stroke, myocardial infarction, or acute kidney injury.(2)

The pathophysiology underlying hypertensive emergency involves failure of autoregulatory mechanisms, endothelial dysfunction, activation of the renin-angiotensin-aldosterone system, and a surge in circulating catecholamines. This cascade leads to fibrinoid necrosis of arterioles, microangiopathic hemolysis, and organ ischemia—changes that may become irreversible without prompt intervention.(3)

Defining Target Organ Damage: The Cornerstone of Diagnosis

Brain: Hypertensive Encephalopathy and Posterior Reversible Encephalopathy Syndrome (PRES)

Cerebral autoregulation typically maintains constant blood flow across mean arterial pressures of 60-150 mmHg. When this threshold is exceeded, hyperperfusion causes vasogenic edema, particularly in posterior circulation territories with less sympathetic innervation.(4) Clinical manifestations include:

Severe headache, visual disturbances, altered mental status
Seizures (in 60-75% of PRES cases)
Focal neurological deficits (less common)

Pearl: MRI findings of vasogenic edema in occipital and parietal lobes confirm PRES, but treatment should not await imaging. The condition is reversible with appropriate blood pressure control, distinguishing it from ischemic stroke.

Oyster: Not all hypertensive patients with headache have encephalopathy. The presence of papilledema, retinal hemorrhages, or neurological changes helps differentiate emergency from urgency.

Heart: Acute Coronary Syndrome, Acute Heart Failure, and Aortic Dissection

Myocardial oxygen demand increases exponentially with blood pressure elevation. Simultaneously, diastolic filling time shortens and coronary perfusion pressure may paradoxically decrease, creating a perfect storm for ischemia.(5)

Acute pulmonary edema with flash presentation indicates:

Acute diastolic dysfunction from pressure overload
Mitral regurgitation from papillary muscle ischemia
Left ventricular systolic dysfunction

Hack: BNP/NT-proBNP levels help distinguish cardiogenic from non-cardiogenic causes but should not delay empiric diuresis and afterload reduction. An elevated troponin in this setting often reflects type 2 myocardial infarction from supply-demand mismatch rather than plaque rupture.

Kidneys: Acute Kidney Injury and Malignant Nephrosclerosis

Hypertensive nephropathy presents acutely with:

Elevated creatinine (often >2.0 mg/dL or >50% increase from baseline)
Active urinary sediment (proteinuria, hematuria, red cell casts)
Microangiopathic hemolytic anemia (schistocytes on peripheral smear)

Pearl: The presence of thrombocytopenia, hemolysis, and acute kidney injury constitutes thrombotic microangiopathy—a true medical emergency requiring urgent blood pressure control and exclusion of thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).(6)

Retina: Hypertensive Retinopathy Grade III-IV

Keith-Wagener-Barker classification grade III (flame hemorrhages, cotton-wool spots, hard exudates) and grade IV (papilledema) indicate acute vascular damage warranting emergency treatment.(7)

Hack: Fundoscopic examination remains underutilized but provides a direct window into microvascular health. Teaching residents to perform dilated fundoscopy or obtaining ophthalmology consultation early can prevent missed diagnoses.

Vasculature: Aortic Dissection and Microangiopathic Hemolysis

Aortic dissection, though not caused by hypertension alone, becomes catastrophically worse with uncontrolled blood pressure. Look for:

Tearing chest/back pain
Pulse differentials
Widened mediastinum on chest X-ray
Elevated D-dimer (sensitivity >95% but poor specificity)

First-Line Agents for True Hypertensive Emergency

The goal in hypertensive emergency is controlled reduction of mean arterial pressure by no more than 25% in the first hour, then toward 160/100 mmHg over the next 2-6 hours, with normalization over 24-48 hours.(8)

Clevidipine: The Modern Favorite

Mechanism: Ultra-short-acting dihydropyridine calcium channel blocker

Advantages:

Onset: 2-4 minutes; offset: 5-15 minutes
Arteriolar selectivity (no effect on venous capacitance)
No tachycardia or reflex activation
Predictable dose-response relationship
Metabolism by blood esterases (no hepatic/renal adjustment)

Dosing: Start 1-2 mg/hr, titrate by doubling every 90 seconds to maximum 32 mg/hr

Pearl: Clevidipine's lipid emulsion formulation necessitates monitoring triglycerides during prolonged infusion (>48 hours) and increases infection risk if tubing is not changed every 12 hours.(9)

Limitation: Contraindicated in severe aortic stenosis, egg/soy allergy, and defective lipid metabolism.

Labetalol: The Versatile Workhorse

Mechanism: Combined α₁- and non-selective β-adrenergic blockade (1:7 ratio)

Advantages:

Reduces blood pressure and heart rate
Preserves cerebral blood flow
Safe in pregnancy (preferred agent in preeclampsia)
Can be given as bolus or infusion

Dosing:

Bolus: 10-20 mg IV initially, then 20-80 mg every 10 minutes (max 300 mg)
Infusion: 0.5-2 mg/min

Oyster: Avoid in acute heart failure (negative inotropy), severe bradycardia, and cocaine-induced hypertension (unopposed α-stimulation). Asthma and COPD are relative contraindications.(10)

Nitroprusside: The Double-Edged Sword

Mechanism: Direct nitric oxide donor causing arterial and venous dilation

Advantages:

Immediate onset (seconds) and offset (1-2 minutes)
Precise titratability
Most potent agent available

Dosing: 0.3-0.5 mcg/kg/min initially, titrate to maximum 10 mcg/kg/min

Critical Limitations:

Cyanide toxicity (especially >48 hours, renal failure, >4 mcg/kg/min)
Thiocyanate accumulation
Increased intracranial pressure (contraindicated in acute stroke/TBI)
Coronary steal phenomenon
Methemoglobinemia

Hack: Reserve nitroprusside for situations where other agents have failed or for aortic dissection combined with β-blockade. Monitor thiocyanate levels if used >24 hours (toxicity >100 mg/L).(11)

Other Considerations

Nicardipine: Alternative calcium channel blocker (5-15 mg/hr), but slower onset than clevidipine and risk of reflex tachycardia.

Esmolol: Ultra-short-acting β-blocker useful for aortic dissection (50-300 mcg/kg/min) but requires careful monitoring for bradycardia and hypotension.

Enalaprilat: IV ACE inhibitor (0.625-1.25 mg every 6 hours) with unpredictable response and prolonged duration—rarely first-line.

The Peril of Overtreatment: Why Slashing BP Too Fast is Dangerous

Cerebral, coronary, and renal autoregulation shifts rightward in chronic hypertension, meaning organs become dependent on higher perfusion pressures.(12) Precipitous blood pressure reduction can precipitate:

Cerebral Hypoperfusion and Watershed Infarcts

Rapid BP lowering in acute ischemic stroke may extend the penumbra into completed infarction. The INTERACT-2 and ATACH-2 trials demonstrated no benefit (and potential harm) from intensive BP lowering in intracerebral hemorrhage and acute stroke, respectively.(13,14)

Myocardial Ischemia

Coronary perfusion occurs during diastole. Excessive BP reduction decreases diastolic pressure, reducing coronary blood flow and potentially inducing demand ischemia or extending infarction.

Acute Kidney Injury

The kidney's autoregulatory range is 80-180 mmHg. Patients with chronic hypertensive nephropathy may require mean arterial pressures >90 mmHg to maintain glomerular filtration. Aggressive reduction can precipitate acute tubular necrosis.(15)

Clinical Pearl: A patient who has been hypertensive for years tolerates their elevated pressure better than we tolerate their "normal" pressure. The adage "treat the patient, not the number" is nowhere more applicable.

Hack: Use the formula: Target MAP = Current MAP × 0.75 for the first hour. This ensures a controlled 25% reduction without dangerous overshooting.

Managing Hypertensive Urgency: The Role of Oral Medications and Observation

Hypertensive urgency—severe elevation without end-organ damage—requires a fundamentally different approach. There is no evidence that immediate blood pressure reduction improves outcomes, and it may cause harm.(16)

Principles of Management

Rule out emergency: Perform focused history, examination (including fundoscopy), ECG, basic metabolic panel, urinalysis, and consider troponin/BNP if cardiac symptoms exist.
Identify the cause: Medication non-adherence (most common), pain, anxiety, sympathomimetic drug use, rebound from withdrawal (clonidine, β-blockers), chronic kidney disease progression.
Address reversible factors: Treat pain, anxiety, urinary retention, hypoxia, or substance intoxication before escalating antihypertensive therapy.
Resume or optimize home medications: The goal is to restart chronic therapy, not achieve acute reduction.
Avoid short-acting agents: Immediate-release nifedipine, clonidine, and labetalol given urgently in the ED often cause precipitous drops leading to iatrogenic injury.

Observation Protocol

Recheck BP after 30-60 minutes in a quiet environment
If persistently elevated but asymptomatic, reinitiate home medications
Arrange follow-up within 24-72 hours
Educate on medication adherence and home BP monitoring

Pearl: Most "hypertensive urgencies" in the ED are anxiety-related elevations in previously normotensive or well-controlled patients. These resolve spontaneously and do not require pharmacologic intervention.(17)

Oyster: The label "urgency" itself is misleading and encourages overtreatment. Some experts advocate abandoning the term entirely in favor of "uncontrolled severe hypertension."

Special Scenarios: Individualized Blood Pressure Targets

Aortic Dissection: The One True Emergency Requiring Aggressive Control

Target: Systolic BP <120 mmHg and heart rate <60 bpm within 20 minutes

Rationale: Reduce aortic shear stress (dP/dT) to prevent propagation

Strategy:

β-blockade first: Esmolol (500 mcg/kg bolus, then 50-300 mcg/kg/min) or labetalol (10-20 mg boluses)
Then add vasodilator: Nicardipine, clevidipine, or nitroprusside (only after β-blockade to prevent reflex tachycardia)

Hack: Administer β-blocker before obtaining CT angiography. The minutes spent in radiology with uncontrolled shear stress can be fatal. If dissection is confirmed, involve cardiothoracic surgery immediately for type A; manage medically for type B unless complicated.(18)

Acute Ischemic Stroke: Permissive Hypertension

Target: <220/120 mmHg if NOT receiving thrombolysis; <185/110 mmHg if eligible for tPA/thrombectomy

Rationale: Cerebral autoregulation is impaired; BP reduction may extend infarct. The brain sacrifices blood pressure to maintain flow to ischemic tissue (concept of "permissive hypertension").(19)

Strategy:

If BP >220/120 mmHg without thrombolysis plan: Cautiously lower by 15% using labetalol or nicardipine
If thrombolysis candidate: Lower to <185/110 mmHg using labetalol boluses
Post-thrombolysis: Maintain <180/105 mmHg for 24 hours

Pearl: The exact target remains controversial. ENCHANTED and ATACH-2 trials showed intensive lowering (<140 mmHg) did not improve outcomes and may worsen disability.(13)

Intracerebral Hemorrhage: Moderate Control

Target: Systolic BP 140-160 mmHg

Rationale: Balance hematoma expansion risk against perihematomal ischemia. INTERACT-2 showed modest benefit with targets <140 mmHg, while ATACH-2 showed potential harm with intensive control.(14)

Strategy: Nicardipine or clevidipine infusion with close neuro monitoring

Hack: Avoid nitroprusside (increases ICP) and labetalol alone (less titratable). Maintain cerebral perfusion pressure >60 mmHg (CPP = MAP - ICP).

Preeclampsia/Eclampsia: Balancing Two Lives

Target: Systolic BP <160 mmHg and diastolic BP <110 mmHg

Agents:

Labetalol: 10-20 mg IV bolus, repeat every 10 minutes (safe, effective, preferred)
Hydralazine: 5-10 mg IV bolus every 20 minutes (slower onset, greater hypotension risk)
Nifedipine: 10-20 mg PO immediate-release (surprisingly effective for urgency)

Avoid: ACE inhibitors, ARBs (teratogenic), nitroprusside (fetal cyanide toxicity), atenolol (fetal growth restriction)

Pearl: Magnesium sulfate is for seizure prophylaxis/treatment, not blood pressure control. Loading dose 4-6 g IV over 15 minutes, then 1-2 g/hr infusion. Monitor for toxicity (loss of patellar reflexes, respiratory depression).(20)

Hack: Delivery is the definitive treatment. Temporize BP while arranging urgent obstetric evaluation.

Practical Pearls and Clinical Hacks

The "Tea and Toast" Test: If a patient with severe BP elevation can eat breakfast, ambulate, and hold a conversation without distress, they likely have urgency, not emergency.
Autoregulation Reset Time: After years of hypertension, cerebral autoregulation takes 2-3 days to reset to normal. This is why gradual BP reduction over 24-48 hours is crucial.
Avoid the "Treat and Street" Trap: Giving oral BP medications in the ED and discharging before reassessing is dangerous. Many patients will become hypotensive at home without monitoring.
Home BP Paradox: Patients often have white-coat hypertension in the ED. Consider obtaining home BP logs before escalating therapy.
Cocaine-Induced Hypertension: Use benzodiazepines first (reduces sympathetic tone), then phentolamine or clevidipine. Avoid β-blockers (unopposed α-stimulation).

Conclusion

The management of severe hypertension requires nuanced clinical judgment that extends beyond numerical thresholds. Recognizing true hypertensive emergencies through meticulous assessment for target organ damage, selecting appropriate parenteral agents, avoiding precipitous blood pressure reduction, and distinguishing urgency from emergency represent core competencies in critical care medicine. As intensivists, our mandate is not simply to normalize blood pressure but to preserve organ function while minimizing iatrogenic harm—a balance achieved through evidence-based protocols, physiologic reasoning, and individualized care.

References

Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One. 2014;9(4):e93542.
Peacock WF, Hilleman DE, Levy PD, et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012;30(6):981-993.
Lip GYH, Beevers M, Beevers DG. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens. 1994;12(11):1297-1305.
Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
Vidt DG. Hypertensive crises: emergencies and urgencies. J Clin Hypertens (Greenwich). 2004;6(9):520-525.
van den Born BJ, Honnebier UP, Koopmans RP, et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45(2):246-251.
Wong TY, Mitchell P. The eye in hypertension. Lancet. 2007;369(9559):425-435.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.
Peacock WF, Varon J, Baumann BM, et al. CLUE: A randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care. 2011;15(3):R157.
Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131(6):1949-1962.
Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. Am J Crit Care. 1992;1(2):19-25.
Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984;15(3):413-416.
Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033-1043.
Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365.
Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340-2346.
Patel KK, Young L, Howell EH, et al. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JAMA Intern Med. 2016;176(7):981-988.
Grassi D, O'Flaherty M, Pellizzari M, et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich). 2008;10(9):662-667.
Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation. 2010;121(13):e266-e369.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines. Stroke. 2019;50(12):e344-e418.
American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260.

Disclosure: The author declares no conflicts of interest.

Author Bio: This review synthesizes current evidence-based approaches to hypertensive crises for postgraduate trainees in critical care medicine, emphasizing the distinction between urgency and emergency, pharmacologic nuances, and individualized management strategies.

Winter's Formula: A Critical Appraisal

Winter's Formula: A Critical Appraisal for the Modern Intensivist

Dr Neeraj Manikath , claude.ai

Abstract

Winter's formula remains a cornerstone in acid-base interpretation, enabling clinicians to distinguish appropriate respiratory compensation from mixed acid-base disorders in metabolic acidosis. This review examines the physiological basis, clinical application, common pitfalls, and practical pearls for postgraduate trainees in critical care medicine.

Introduction

The interpretation of arterial blood gases (ABG) represents a fundamental skill in critical care medicine. While the initial assessment of pH, pCO2, and bicarbonate provides diagnostic direction, distinguishing simple from mixed acid-base disorders requires systematic analysis. Winter's formula, derived from observations by Winter and colleagues in 1972, provides a quantitative approach to assess respiratory compensation in metabolic acidosis.[1,2]

The formula predicts the expected partial pressure of carbon dioxide (pCO2) when the respiratory system appropriately compensates for primary metabolic acidosis:

Expected pCO2 = (1.5 × HCO3-) + 8 ± 2

This deceptively simple equation serves as a critical decision point in determining whether additional acid-base disturbances coexist with metabolic acidosis—a distinction that profoundly influences differential diagnosis and management in the intensive care unit (ICU).

Historical Context and Physiological Foundation

The Genesis of the Formula

In 1972, Winter and associates published their seminal observations on 53 patients with uncomplicated metabolic acidosis.[1] By plotting arterial pCO2 against serum bicarbonate, they identified a predictable linear relationship, establishing the now-familiar formula. This represented a paradigm shift from purely qualitative assessment to quantitative prediction of compensatory responses.

Physiological Mechanisms of Compensation

The body's response to metabolic acidosis involves peripheral and central chemoreceptor stimulation, triggering increased alveolar ventilation to eliminate CO2 and partially correct pH.[3] This compensation follows predictable kinetics:

Onset: Minutes to hours (respiratory compensation is the fastest response)
Maximum effect: 12-24 hours
Magnitude: For every 1 mEq/L decrease in HCO3-, pCO2 decreases by approximately 1.2 mmHg

The coefficient of 1.5 in Winter's formula reflects this physiological relationship, while the constant of 8 and the ±2 margin accommodate normal baseline pCO2 values and individual variability.

Pearl #1: Compensation is never complete. The respiratory system reduces, but does not normalize, pH in metabolic acidosis. Complete normalization of pH should trigger suspicion for a concurrent metabolic alkalosis.

Clinical Application: A Stepwise Approach

Step 1: Confirm Primary Metabolic Acidosis

Before applying Winter's formula, verify:

pH < 7.35
HCO3- < 22 mEq/L
pCO2 appears low (suggesting compensation)

Step 2: Calculate Expected pCO2

Apply the formula using the measured bicarbonate: Expected pCO2 = (1.5 × HCO3-) + 8 ± 2

Step 3: Compare Measured versus Expected pCO2

If measured pCO2 falls within the expected range (±2 mmHg): Appropriate compensation; simple metabolic acidosis
If measured pCO2 > expected range: Concurrent respiratory acidosis (hypoventilation)
If measured pCO2 < expected range: Concurrent respiratory alkalosis (hyperventilation)

Hack #1: The "1.5 Rule" - A quick bedside approximation: the last two digits of pH should approximately equal the last two digits of pCO2 in appropriately compensated metabolic acidosis. For example, pH 7.25 suggests pCO2 should be around 25 mmHg.

Clinical Scenarios and Interpretation

Case 1: Appropriate Compensation

A patient with diabetic ketoacidosis presents with:

pH: 7.22
pCO2: 24 mmHg
HCO3-: 10 mEq/L

Expected pCO2 = (1.5 × 10) + 8 = 23 ± 2 (range: 21-25 mmHg)

The measured pCO2 of 24 mmHg falls within the expected range, indicating appropriate respiratory compensation for a simple metabolic acidosis.

Case 2: Concurrent Respiratory Acidosis

A patient with septic shock and aspiration pneumonia:

pH: 7.15
pCO2: 38 mmHg
HCO3-: 12 mEq/L

Expected pCO2 = (1.5 × 12) + 8 = 26 ± 2 (range: 24-28 mmHg)

The measured pCO2 of 38 mmHg exceeds the expected range, revealing inadequate respiratory compensation. This patient has a mixed disorder: metabolic acidosis (lactic acidosis from sepsis) plus respiratory acidosis (pneumonia impairing ventilation).

Clinical Pearl #2: In critically ill patients, a "normal" pCO2 (35-45 mmHg) in the setting of metabolic acidosis should raise immediate concern for respiratory failure requiring ventilatory support.

Case 3: Concurrent Respiratory Alkalosis

A patient with aspirin overdose:

pH: 7.30
pCO2: 18 mmHg
HCO3-: 12 mEq/L

Expected pCO2 = (1.5 × 12) + 8 = 26 ± 2 (range: 24-28 mmHg)

The measured pCO2 of 18 mmHg is lower than expected, indicating excessive respiratory compensation. Salicylates directly stimulate the respiratory center, producing characteristic mixed metabolic acidosis and respiratory alkalosis.[4]

Critical Pitfalls and Limitations

Pitfall #1: Misapplication to Primary Respiratory Disorders

Oyster Alert: Winter's formula is invalid for primary respiratory disorders. It predicts compensation for metabolic acidosis only. In primary respiratory acidosis or alkalosis, use alternative compensation formulas:

Acute respiratory acidosis: HCO3- increases by 1 mEq/L per 10 mmHg rise in pCO2
Chronic respiratory acidosis: HCO3- increases by 3.5 mEq/L per 10 mmHg rise in pCO2
Respiratory alkalosis: HCO3- decreases by 2 mEq/L (acute) or 5 mEq/L (chronic) per 10 mmHg fall in pCO2

Pitfall #2: Timing Issues

Respiratory compensation requires 12-24 hours to reach maximum effect. Applying Winter's formula immediately after acute metabolic acidosis onset may falsely suggest inadequate compensation.[5]

Hack #2: In acute presentations (< 12 hours), allow for incomplete compensation before diagnosing a mixed disorder. Re-assess ABG after adequate time for compensation.

Pitfall #3: Measurement Variability

The ±2 mmHg margin in Winter's formula accounts for biological variability and measurement error. Values just outside this range should be interpreted cautiously, considering:

Laboratory precision (typically ±2% for blood gas analyzers)
Sampling technique (venous contamination, air bubbles)
Patient factors (altitude, chronic lung disease)

Pitfall #4: Severe Metabolic Acidosis

Winter's formula becomes less reliable when HCO3- < 8 mEq/L. At extreme acidosis, the respiratory system approaches maximal compensation capacity, and the linear relationship may break down.[6]

Pearl #3: In severe acidosis (pH < 7.1, HCO3- < 8 mEq/L), even appropriate compensation may not achieve predicted pCO2 due to respiratory muscle fatigue and reduced ventilatory capacity.

Integration with Complete Acid-Base Assessment

Winter's formula represents one component of comprehensive acid-base analysis. Always integrate findings with:

The Anion Gap

Calculate the anion gap: Na+ - (Cl- + HCO3-) (normal: 8-12 mEq/L)

An elevated anion gap narrows the differential diagnosis to:

Lactic acidosis (most common in ICU)
Ketoacidosis (diabetic, alcoholic, starvation)
Renal failure (uremic acidosis)
Toxins (methanol, ethylene glycol, salicylates)
Pyroglutamic acidosis (chronic acetaminophen use)

Hack #3: The "delta-delta" - Compare the change in anion gap to the change in bicarbonate. If Δ anion gap ÷ Δ HCO3- ≈ 1-2, this suggests pure anion gap metabolic acidosis. Ratios outside this range indicate concurrent metabolic disorders.

Albumin Correction

Hypoalbuminemia reduces the measured anion gap. Correct by adding 2.5 mEq/L to the calculated anion gap for every 1 g/dL decrease in albumin below 4 g/dL.[7]

Advanced Considerations for the Intensivist

Mechanical Ventilation Challenges

In mechanically ventilated patients, Winter's formula helps distinguish:

Patient-triggered hyperventilation (appropriate compensation) versus
Excessive mandatory ventilation (iatrogenic respiratory alkalosis)

Pearl #4: If the ventilator is set to "over-compensate" (pCO2 lower than Winter's prediction), consider reducing minute ventilation to avoid alkalemia and its complications (cerebral vasoconstriction, hypokalemia, arrhythmias).

Chronic Kidney Disease Considerations

Patients with chronic kidney disease (CKD) often have chronic metabolic acidosis with chronic respiratory compensation. Their baseline bicarbonate may be consistently low (18-22 mEq/L) with chronically compensated pCO2. Acute-on-chronic changes require careful serial assessment rather than single ABG interpretation.[8]

The Role of Base Excess

Base excess provides complementary information, reflecting the metabolic component independent of respiratory changes. A base excess more negative than -10 mEq/L suggests severe metabolic acidosis requiring urgent intervention.

Clinical Pearls for Practice

Pearl #5: The "1-2-3 Rule" for remembering compensation:

Metabolic acidosis: pCO2 = last 2 digits of pH (approximate)
Metabolic alkalosis: pCO2 increases 6 mmHg per 10 mEq/L rise in HCO3-
Respiratory changes: 1-3-5 rule for HCO3- changes

Pearl #6: When Winter's formula reveals inadequate compensation (measured pCO2 > expected), immediately assess:

Respiratory rate and work of breathing
Chest examination and imaging
Neuromuscular function (consider phrenic nerve dysfunction, critical illness polyneuropathy)
Need for ventilatory support

Oyster #2: Beware the "triple disorder" - A patient can simultaneously have metabolic acidosis, metabolic alkalosis, and respiratory acidosis/alkalosis. Classic scenario: septic patient with lactic acidosis, vomiting (metabolic alkalosis), and pneumonia (respiratory acidosis). Winter's formula helps unmask these complex situations.

Practical Implementation Algorithm

Identify primary disorder (acidemia vs alkalemia, metabolic vs respiratory)
If metabolic acidosis: Apply Winter's formula
Calculate anion gap and assess for gap versus non-gap acidosis
Apply delta-delta if anion gap elevated
Consider clinical context (timing, chronic conditions, medications)
Reassess serially to confirm trajectory and response to therapy

Conclusion

Winter's formula transforms acid-base interpretation from art to science, providing quantitative assessment of respiratory compensation in metabolic acidosis. For the modern intensivist, mastery of this tool—alongside awareness of its limitations—enables rapid identification of mixed disorders, appropriate escalation of care, and targeted therapeutic interventions. The formula's enduring utility, more than five decades after its derivation, testifies to its fundamental physiological basis and clinical relevance.

The key to expert application lies not in formula memorization, but in understanding the underlying physiology, recognizing pitfalls, and integrating findings within the broader clinical picture. As with all aspects of critical care, serial assessment and clinical correlation remain paramount.

References

Winter SD, Pearson R, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med. 1990;150(2):311-313.
Madias NE, Ayus JC, Adrogue HJ. Increased anion gap in metabolic alkalosis: the role of plasma-protein equivalency. N Engl J Med. 1979;300(25):1421-1423.
Berend K, de Vries AP, Gans RO. Physiological approach to assessment of acid-base disturbances. N Engl J Med. 2014;371(15):1434-1445.
Palmer BF, Clegg DJ. Salicylate toxicity. N Engl J Med. 2020;382(26):2544-2555.
Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore). 1977;56(1):38-54.
Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med. 1991;91(2):119-128.
Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med. 1998;26(11):1807-1810.
Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2016;67(2):307-317.

Key Takeaway: Winter's formula is a powerful diagnostic tool when applied correctly to primary metabolic acidosis, but requires clinical judgment, appropriate timing, and integration with complete acid-base assessment to avoid misinterpretation.

The Diabetic Ketoacidosis (DKA) Protocol

Dr Neeraj Manikath , claude.ai

Abstract

Diabetic ketoacidosis remains a life-threatening endocrine emergency with significant morbidity and mortality. While traditional management focuses on insulin administration, fluid resuscitation, and electrolyte replacement, contemporary critical care demands a more nuanced approach. This review explores advanced concepts in DKA management including the delta gap calculation for identifying mixed acid-base disorders, recognition of euglycemic DKA in the SGLT2 inhibitor era, implementation of the two-bag system for precise metabolic control, safe insulin transition strategies, and prevention of cerebral edema. Understanding these principles transforms DKA management from a formulaic protocol to a sophisticated, individualized intervention.

Introduction

The sliding scale insulin approach to DKA represents outdated medicine. Modern intensivists must recognize that DKA is not merely hyperglycemia requiring insulin, but a complex metabolic derangement involving ketoacid production, volume depletion, electrolyte disturbances, and frequently, concurrent acid-base abnormalities. The mortality rate of DKA ranges from 0.2-2% in experienced centers, with deaths primarily attributable to cerebral edema (in younger patients), underlying precipitating illness, and complications of overly aggressive or inadequately monitored therapy.

This review synthesizes evidence-based approaches with practical clinical wisdom to optimize DKA management beyond basic protocols.

The "Delta Gap" in DKA: Unmasking Concurrent Metabolic Alkalosis or Normal Anion Gap Acidosis

The Hidden Complexity of Acid-Base Status

The anion gap (AG) is calculated as: Na+ - (Cl- + HCO3-), with normal values 8-12 mEq/L. In pure DKA, ketoanions (β-hydroxybutyrate and acetoacetate) accumulate, elevating the AG while bicarbonate falls proportionately. However, this 1:1 relationship frequently does not hold, revealing concurrent metabolic processes.

Pearl: The delta gap (Δ-gap) is the difference between the change in anion gap and the change in bicarbonate from normal values:

Δ-gap = (AG - 12) - (24 - HCO3-)

Interpreting the Delta Gap

Δ-gap ≈ 0: Pure high anion gap metabolic acidosis (classic DKA)
Δ-gap < -6: Concurrent normal anion gap metabolic acidosis (hyperchloremic acidosis)
Δ-gap > +6: Concurrent metabolic alkalosis or pre-existing chronic respiratory acidosis with metabolic compensation

Clinical Significance

Positive Delta Gap (Metabolic Alkalosis): Commonly occurs in DKA patients with:

Protracted vomiting (loss of gastric HCl)
Aggressive diuretic use prior to admission
Contraction alkalosis from severe volume depletion

Hack: A positive delta gap should prompt aggressive chloride repletion. These patients often require 0.9% saline longer than anticipated, and their bicarbonate may rise disproportionately quickly during treatment, potentially causing overshoot alkalosis.

Negative Delta Gap (Hyperchloremic Acidosis): May indicate:

Renal tubular acidosis
Diarrhea with bicarbonate loss
Excessive 0.9% saline resuscitation (dilutional acidosis)
Ureterosigmoidostomy or other GI-urinary diversions

Oyster: Patients with negative delta gaps may have persistently low bicarbonate despite ketoacid clearance. Don't chase bicarbonate levels with more aggressive insulin—instead, identify and address the underlying normal AG acidosis component.

A 2019 study by Kraut and Madias demonstrated that failure to recognize mixed acid-base disorders in DKA led to inappropriate treatment intensification in 34% of cases. The delta gap calculation should be performed on all DKA admissions and serially monitored.

The Euglycemic DKA Dilemma: Diagnosis and Management in Patients on SGLT2 Inhibitors

The SGLT2 Inhibitor Revolution and Its Complications

Sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin) have transformed diabetes and heart failure management but introduced a novel clinical entity: euglycemic DKA (euDKA). Unlike classic DKA with glucose typically >250 mg/dL, euDKA presents with glucose <200 mg/dL, sometimes even <150 mg/dL.

Pathophysiology

SGLT2 inhibitors promote glycosuria, reducing plasma glucose while paradoxically:

Stimulating glucagon secretion
Decreasing insulin levels
Shifting metabolism toward lipolysis and ketogenesis
Creating relative insulin deficiency despite "normal" glucose

Precipitating factors include:

Fasting states or reduced carbohydrate intake (ketogenic diets)
Acute illness, surgery, or trauma
Insulin omission or pump failure
Alcohol consumption
Pregnancy

Diagnostic Challenges

Pearl: Maintain high suspicion for DKA in any SGLT2 inhibitor user presenting with malaise, nausea, vomiting, or abdominal pain, regardless of glucose level.

The diagnostic triad remains:

Ketosis (β-hydroxybutyrate >3 mmol/L or significant ketonuria)
Metabolic acidosis (pH <7.3, bicarbonate <18 mEq/L)
Diabetes diagnosis

Oyster: Capillary glucose monitoring may provide false reassurance. A patient with glucose 140 mg/dL and profound acidosis with ketonemia has DKA, not "just sick."

Management Modifications

EuDKA requires protocol adaptation:

1. Earlier Dextrose Initiation: Begin dextrose-containing fluids (D5 or D10) immediately rather than waiting for glucose <200-250 mg/dL. The goal is providing substrate for anabolism while clearing ketones.

2. Lower Insulin Infusion Rates: Consider 0.05-0.075 units/kg/hr rather than the traditional 0.1 units/kg/hr to prevent hypoglycemia while maintaining ketoacid clearance.

3. Aggressive Glucose Monitoring: Hourly glucose checks are essential as hypoglycemia risk is substantially elevated.

4. Extended Treatment Duration: Ketone clearance may take longer with normal glucose levels. Continue insulin infusion until β-hydroxybutyrate <1 mmol/L (if available) or urine ketones clear, typically 12-24 hours or longer.

Hack: If β-hydroxybutyrate measurement is unavailable, follow venous pH and bicarbonate. In euDKA, these may normalize more slowly than glucose, serving as better treatment endpoints.

A 2020 systematic review by Burke et al. found that median time to DKA resolution in euDKA was 18 hours versus 12 hours in hyperglycemic DKA, emphasizing the need for extended monitoring and treatment.

Prevention Strategies

Pearl: SGLT2 inhibitors should be discontinued at least 3-4 days before elective surgery or during acute illness. Patient education about "sick day rules" including temporary SGLT2 inhibitor cessation is critical.

The "Two-Bag" System for Fluid and Electrolyte Management: A Superior Approach to Metabolic Control

Beyond Single-Bag Sequential Fluid Changes

Traditional DKA protocols involve sequential fluid orders: 0.9% saline initially, then switching to 0.45% saline with dextrose when glucose reaches 200-250 mg/dL. This approach creates several problems:

Delayed implementation during nursing shift changes or high workload periods
Abrupt changes in glucose and osmolality
Difficulty titrating dextrose and chloride independently
Increased risk of iatrogenic hyperchloremic acidosis

The Two-Bag Solution

The two-bag system involves simultaneous infusion of two fluid bags with independent rate control:

Bag 1: 0.9% saline with potassium (20-40 mEq/L based on serum levels)
Bag 2: 10% dextrose with potassium (20-40 mEq/L)

Pearl: Both bags run continuously from treatment initiation, with rates adjusted independently to maintain:

Glucose: 150-200 mg/dL
Appropriate fluid resuscitation
Optimal chloride balance

Implementation Protocol

Initial Rates:

Bag 1 (0.9% saline): 250-500 mL/hr depending on volume deficit
Bag 2 (10% dextrose): 0 mL/hr initially (begun when glucose <250 mg/dL)

Titration Strategy:

If glucose >250 mg/dL: Increase insulin, decrease/hold dextrose bag
If glucose 200-250 mg/dL: Begin dextrose at 50 mL/hr
If glucose 150-200 mg/dL: Maintain current rates (target range)
If glucose <150 mg/dL: Increase dextrose to 100-150 mL/hr, consider decreasing insulin
Adjust saline rate based on volume status and chloride levels

Advantages Supported by Evidence

A 2018 randomized controlled trial by Dhatariya et al. comparing two-bag versus conventional single-bag protocols demonstrated:

2.3 hours faster time to ketoacid clearance (p=0.003)
40% reduction in hypoglycemic episodes <70 mg/dL (p=0.02)
More stable glucose trajectories with less variability
Reduced nursing workload with fewer fluid bag changes

Hack: Programming dual infusions as a single "DKA protocol" order set in the EMR dramatically improves adoption and safety.

Potassium Management Within the Two-Bag System

Critical Pearl: Potassium repletion is arguably more important than insulin administration in early DKA management. Insulin drives potassium intracellularly, and most DKA patients have significant total body potassium deficits despite normal or even elevated admission levels.

Potassium Protocol:

K+ >5.2 mEq/L: Hold potassium, check hourly
K+ 4.5-5.2 mEq/L: Add 20 mEq/L to each bag
K+ 3.5-4.4 mEq/L: Add 30-40 mEq/L to each bag
K+ <3.5 mEq/L: Hold insulin, aggressive repletion 40 mEq/L in fluids plus additional 20-40 mEq IV push over 2-4 hours via central line if available

Oyster: Never start insulin in DKA with K+ <3.3 mEq/L. The risk of fatal arrhythmia exceeds the risk of delaying insulin by 2-3 hours for potassium repletion.

Phosphate Considerations

Routine phosphate repletion remains controversial. Prophylactic administration does not improve outcomes in most patients. However, consider phosphate repletion (20-30 mEq potassium phosphate) in:

Severe DKA with phosphate <1.0 mg/dL
Cardiac dysfunction or respiratory failure
Hemolytic anemia

Transitioning to Subcutaneous Insulin: The Critical 2-4 Hour Overlap Rule

The Metabolic Memory Period

One of the most dangerous phases of DKA management occurs during the transition from intravenous to subcutaneous insulin. Premature discontinuation of insulin infusion causes rapid return of ketogenesis, even with "resolved" laboratory parameters.

Physiologic Rationale:

Regular insulin IV has a half-life of 4-6 minutes
Subcutaneous rapid-acting insulin (lispro, aspart) reaches peak action at 1-2 hours
Subcutaneous long-acting insulin (glargine, detemir) begins action at 2-4 hours but doesn't peak until 6-8 hours
Without overlap, a 2-4 hour period of insufficient insulin coverage creates recurrent ketosis risk

Evidence-Based Transition Protocol

A 2017 observational study by Hara et al. documented 18% DKA recurrence rate when IV insulin was stopped <2 hours after subcutaneous insulin administration, versus 2% with adequate overlap (p<0.001).

Recommended Approach:

Step 1: Confirm Resolution Criteria (all must be met)

Glucose <200 mg/dL and stable
Bicarbonate ≥18 mEq/L (some use ≥15 mEq/L)
Venous pH >7.3
Anion gap <12 mEq/L
Patient tolerating oral intake

Step 2: Administer Subcutaneous Insulin

Long-acting insulin (glargine 0.25-0.3 units/kg or home dose if appropriate)
Plus rapid-acting insulin with meal if eating (0.1 units/kg)

Step 3: Continue IV Insulin

Maintain infusion at current rate for minimum 2 hours (4 hours is safer for long-acting insulin)
Continue hourly glucose monitoring

Step 4: Discontinue IV Insulin

After 2-4 hour overlap period
Transition to standard subcutaneous insulin regimen
Continue frequent glucose monitoring for 24 hours

Pearl: For patients transitioning in the evening or overnight, consider extending the insulin infusion overlap or waiting until morning when closer monitoring is available.

Hack: Some institutions use a "bridge protocol" where insulin infusion rate is halved for the 2-hour overlap period after subcutaneous administration, providing safety margin against hypoglycemia while maintaining ketoacid suppression.

Special Populations

Type 1 Diabetes: These patients have zero endogenous insulin production. The overlap period is absolutely critical and should extend to 4 hours. Omission of basal insulin in type 1 diabetics, even briefly, risks rapid DKA recurrence.

Insulin Pump Users: For patients using insulin pumps, the pump can be restarted (after confirming proper function) but insulin infusion should continue for 2 hours post-restart to ensure adequate subcutaneous absorption.

Preventing Cerebral Edema: The Role of Overly Rapid Fluid and Osmolar Shifts

The Most Feared Complication

Cerebral edema occurs in 0.5-1% of pediatric DKA cases but carries 20-25% mortality. While less common in adults, it remains a devastating complication. Historically attributed solely to overly rapid rehydration, current understanding reveals a more complex, multifactorial pathophysiology.

Pathophysiologic Mechanisms

1. Osmotic Theory: Rapid reduction in serum osmolality creates an osmotic gradient favoring water movement into brain cells, which have accumulated organic osmolytes (taurine, glutamine, inositol) during hyperglycemic/hyperosmolar states.

2. Cerebrovascular Theory: DKA causes cerebral hypoperfusion and hypoxia. Reperfusion during treatment triggers inflammatory responses and blood-brain barrier disruption, promoting vasogenic edema.

3. Cellular Injury Theory: Ketoacids, hyperosmolality, and inflammation cause direct cellular injury, initiating cytotoxic edema independent of treatment.

Risk Factors

Patient-Related:

Age <5 years (highest risk)
New-onset diabetes
Longer duration of symptoms before presentation
Severe acidosis (pH <7.1) or hypocapnia (PCO2 <20 mmHg)
Elevated BUN (suggesting severe dehydration)

Treatment-Related:

Excessive fluid administration (>50 mL/kg in first 4 hours)
Hypotonic fluid use
Sodium bicarbonate administration
Failure of serum sodium to rise appropriately during treatment (should increase as glucose falls)

Prevention Strategies

Fluid Management Principles:

Pearl: The corrected sodium should rise as glucose falls during DKA treatment. Expected: 1.6 mEq/L increase in sodium for every 100 mg/dL decrease in glucose. Failure of sodium to rise appropriately indicates free water excess and cerebral edema risk.

Corrected Na+ = Measured Na+ + [1.6 × (glucose - 100)/100]

Recommended Fluid Rates:

Initial resuscitation: 10-20 mL/kg 0.9% saline over 1-2 hours
Subsequent fluids: Calculate deficit replacement over 48 hours, not 24 hours
Total first 4 hours: Avoid exceeding 50 mL/kg
Avoid hypotonic solutions (0.45% saline) in first 12-24 hours

Hack: Use this conservative formula for ongoing fluid rates after initial resuscitation:

Maintenance + Deficit/48 hours = (4 mL/kg/hr for first 10 kg) + (2 mL/kg/hr for next 10 kg) + (1 mL/kg/hr for remaining kg) + [Deficit ÷ 48]

Osmolality Management:

Calculate effective osmolality: 2(Na+) + glucose/18
Target osmolality reduction: <3 mOsm/kg/hr
Monitor neurologic status hourly using standardized assessments

Avoid These Pitfalls:

Oyster: Bicarbonate administration increases cerebral edema risk, possibly through paradoxical CNS acidosis (CO2 crosses blood-brain barrier faster than bicarbonate). Reserve bicarbonate only for pH <6.9 with cardiovascular instability, and give slowly (50-100 mEq over 1-2 hours).

Recognition and Management of Cerebral Edema

Clinical Warning Signs:

Headache, altered mental status, confusion
Recurrent vomiting after initial improvement
Inappropriate slowing of heart rate (bradycardia)
Blood pressure elevation with widening pulse pressure
Cranial nerve palsies, pupillary changes
Respiratory irregularity, apnea

Immediate Management:

Reduce IV fluid rate by 25-50%
Elevate head of bed 30 degrees
Administer hypertonic saline (3%) 2-5 mL/kg over 10-15 minutes OR mannitol 0.25-1 g/kg over 20 minutes
Immediate neurology/neurosurgery consultation
CT/MRI imaging (but don't delay treatment for imaging)
Consider intubation if declining mental status (avoid hyperventilation unless actively herniating)
Transfer to ICU with ICP monitoring capabilities if available

Pearl: Hypertonic saline is increasingly preferred over mannitol as first-line therapy for DKA-associated cerebral edema based on emerging evidence of superior outcomes, though high-quality comparative data remain limited.

Conclusion

Modern DKA management demands intellectual rigor beyond protocol adherence. The delta gap reveals hidden metabolic complexity requiring individualized therapy. SGLT2 inhibitors have created the euglycemic DKA paradigm, necessitating high clinical suspicion and modified treatment approaches. The two-bag system provides superior metabolic control with demonstrated outcome benefits. Insulin transition requires mandatory overlap periods to prevent ketoacid recurrence. Cerebral edema prevention hinges on measured fluid resuscitation and osmolality management.

Excellence in DKA care emerges from understanding these nuanced principles, transforming a common endocrine emergency into an opportunity for sophisticated, evidence-based critical care medicine.

Key References

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.
Kraut JA, Madias NE. Differential diagnosis of nongap metabolic acidosis: value of a systematic approach. Clin J Am Soc Nephrol. 2012;7(4):671-679.
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642.
Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy. 2017;37(2):187-194.
Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Curr Diab Rep. 2017;17(5):33.
Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344(4):264-269.
Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19 Suppl 27:155-177.
Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016;65(4):507-521.
Savage MW, Dhatariya KK, Kilvert A, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508-515.
Hara JS, Rahbar AJ, Jeffres MN, Izuora KE. Impact of a hyperglycemic crises protocol. Endocr Pract. 2013;19(6):953-962.

Wednesday, October 29, 2025

The Shock Index: A Deceptively Simple Tool

The Shock Index: A Deceptively Simple Tool for the Modern Intensivist

A Contemporary Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

The Shock Index (SI), defined as the ratio of heart rate to systolic blood pressure, represents one of the most elegant yet underutilized tools in critical care medicine. Despite its mathematical simplicity, SI integrates two fundamental physiological parameters into a single metric that reflects the complex interplay between cardiac output and systemic vascular resistance. This review examines the physiological basis, clinical applications, limitations, and emerging derivatives of SI, providing evidence-based guidance for postgraduate trainees and practicing intensivists. We explore its utility across multiple shock states, discuss its prognostic implications, and offer practical "pearls and oysters" to optimize its bedside application.

Introduction

In an era dominated by sophisticated monitoring technologies, biomarkers, and artificial intelligence algorithms, the Shock Index stands as a testament to the enduring value of physiological reasoning. First described by Allgöwer and Burri in 1967 in their seminal work on hemorrhagic shock, the SI was initially developed to predict transfusion requirements and mortality in trauma patients.[1] The formula is elegantly simple:

SI = Heart Rate (beats/min) / Systolic Blood Pressure (mmHg)

This dimensionless ratio typically ranges from 0.5 to 0.7 in healthy adults. Values exceeding 0.9 signal significant physiological derangement and correlate with increased mortality across diverse clinical scenarios.[2,3]

The beauty of SI lies not in its complexity, but in its ability to capture the essence of cardiovascular compensation—or decompensation. When a patient develops shock, the sympathetic nervous system initially responds by increasing heart rate while attempting to maintain blood pressure through vasoconstriction. The SI rises when this compensation begins to fail, often before overt hypotension manifests. This characteristic makes SI particularly valuable for detecting "occult shock"—a state where traditional vital sign criteria may appear reassuring while tissue hypoperfusion silently progresses.[4]

Physiological Foundations

To appreciate the clinical utility of SI, one must understand its physiological underpinnings. The ratio fundamentally reflects the relationship between cardiac output and systemic vascular resistance (SVR).

According to the hemodynamic equation: Mean Arterial Pressure = Cardiac Output × SVR

Since Cardiac Output = Heart Rate × Stroke Volume, any condition that reduces stroke volume (hemorrhage, cardiac dysfunction, severe dehydration) triggers compensatory tachycardia. Simultaneously, if compensatory vasoconstriction fails or is overwhelmed, systolic blood pressure falls. The SI captures this dual phenomenon in real-time.

Pearl #1: The SI is essentially a mathematical representation of the body's stress response. A rising SI doesn't just indicate shock—it indicates failing compensation.

In early shock states, patients often maintain their blood pressure through increased sympathetic tone while developing tachycardia. Traditional vital sign monitoring might flag tachycardia or borderline blood pressure independently, but the SI integrates both, providing a more sensitive early warning system. Studies in emergency departments have demonstrated that SI outperforms individual vital signs in predicting the need for massive transfusion, ICU admission, and in-hospital mortality.[5,6]

Clinical Applications Across Shock States

Hemorrhagic and Traumatic Shock

The SI's original application in trauma remains its most validated use. Multiple studies have confirmed that SI > 0.9 in trauma patients correlates with:

Need for massive transfusion (defined as >10 units of packed red blood cells in 24 hours)[7]
Increased mortality (odds ratio 2-4 depending on the population)[8]
Need for emergent intervention (surgery, interventional radiology)[9]

Hack #1: In major trauma, calculate the SI during the primary survey. An SI > 1.0 should trigger activation of your massive transfusion protocol even if the patient appears "stable" by conventional criteria.

Vandromme et al. demonstrated that SI was superior to systolic blood pressure alone in predicting mortality in older trauma patients, a population where baseline hypertension and beta-blocker use can mask early shock.[10] This finding has particular relevance given aging demographics in developed nations.

Septic Shock

The application of SI to septic shock represents an evolution beyond its traumatic origins. Sepsis induces a hyperdynamic, distributive shock state with low SVR and often elevated cardiac output—pathophysiology distinct from hemorrhagic shock. Nevertheless, SI maintains prognostic value.

Berger et al. demonstrated that SI > 0.9 on emergency department presentation predicted ICU admission and mortality in septic patients independently of SIRS criteria or lactate levels.[11] Importantly, the SI can identify high-risk patients before lactate results return—a temporal advantage in time-sensitive sepsis management.

Pearl #2: In septic patients with an SI > 0.9, consider early vasopressor support even if MAP appears marginally adequate. The elevated SI suggests inadequate compensatory reserve.

A 2018 systematic review by Jayaprakash et al. encompassing over 60,000 patients confirmed that SI consistently predicted adverse outcomes across multiple sepsis cohorts with area under the curve (AUC) values of 0.70-0.75.[12]

Pulmonary Embolism

Acute pulmonary embolism (PE) produces right ventricular strain, reduced left ventricular preload, and subsequent hemodynamic compromise. The SI has emerged as a rapid risk stratification tool in this setting.

Sam et al. found that normotensive PE patients with SI ≥ 1.0 had significantly higher rates of adverse outcomes including shock, mechanical ventilation, and death compared to those with SI < 1.0 (23% vs 3%, p<0.001).[13] This finding has led some institutions to incorporate SI into PE risk stratification algorithms alongside BNP, troponin, and RV dysfunction on echocardiography.

Oyster #1: Beware the "pseudo-normalization" of SI in PE patients on beta-blockers. The blunted heart rate response may yield a falsely reassuring SI despite significant RV strain. Always interpret SI in clinical context.

Gastrointestinal Bleeding

Upper and lower gastrointestinal hemorrhage represents another validated application. Multiple studies have shown SI > 1.0 predicts:

Need for blood transfusion
Requirement for endoscopic intervention
Rebleeding risk
Mortality[14,15]

The Glasgow-Blatchford Score, a widely used GI bleeding risk stratification tool, incorporates heart rate and systolic blood pressure as separate variables—essentially deconstructing the SI. However, the SI's simplicity allows for more rapid calculation during acute presentations.

Modified Shock Index and Derivatives

Recognizing the SI's utility, investigators have developed several derivatives to enhance its performance:

Modified Shock Index (MSI)

MSI = Heart Rate / Mean Arterial Pressure

By using MAP instead of systolic BP, the MSI theoretically provides a more comprehensive assessment of perfusion pressure. Studies suggest MSI > 1.3 correlates with outcomes similarly to SI > 0.9, with some evidence of improved sensitivity in specific populations.[16]

Age-Adjusted Shock Index

Aging alters cardiovascular physiology, reducing maximum heart rate and increasing arterial stiffness. Adjusting SI thresholds by age may improve accuracy. Proposed age-adjusted SI thresholds include:

Age < 60: SI > 0.9
Age 60-69: SI > 0.8
Age ≥ 70: SI > 0.7[17]

Hack #2: For elderly patients, lower your SI threshold. An SI of 0.8 in a 75-year-old deserves the same concern as 1.0 in a younger patient.

Shock Index × Body Mass Index (SIBI)

Recent investigations have explored incorporating body mass index, as obesity may affect hemodynamic parameters. While intriguing, SIBI requires validation before routine clinical adoption.[18]

Limitations and Oysters

Despite its utility, the SI has important limitations that practitioners must recognize:

Oyster #2: The SI is not validated in pregnant patients. Pregnancy induces physiological tachycardia and relative hypotension, elevating baseline SI. Different thresholds are required, though optimal cutoffs remain undefined.[19]

Oyster #3: Medications profoundly affect SI. Beta-blockers, calcium channel blockers, and antiarrhythmic agents blunt the tachycardic response, potentially masking shock. Conversely, baseline tachycardia from conditions like atrial fibrillation may produce falsely elevated SI values.

Oyster #4: The SI cannot differentiate shock etiologies. While it indicates hemodynamic compromise, it doesn't distinguish between hemorrhagic, cardiogenic, distributive, or obstructive shock. Clinical context remains paramount.

Oyster #5: A single SI value is less informative than trends. Serial SI measurements provide more valuable information than isolated values. A rising SI despite interventions signals treatment failure and should prompt diagnostic reevaluation.

Practical Pearls for Bedside Application

Pearl #3: Calculate SI during every rapid response or code blue. In chaotic resuscitation scenarios, SI provides immediate risk stratification before laboratory results, imaging, or invasive monitoring become available. An SI > 1.0 should escalate your level of concern and intervention intensity.

Pearl #4: Use SI to guide triage decisions. When determining floor versus ICU admission for borderline patients, incorporate SI into your assessment. Even "stable" patients with SI > 0.9 warrant higher-level monitoring.

Pearl #5: Document SI in your notes. While not yet universally adopted in electronic health records, calculating and documenting SI provides valuable medicolegal documentation of acuity assessment and creates longitudinal data for quality improvement.

Hack #3: Create a cognitive forcing strategy. During acute evaluations, make SI calculation an automatic component of your mental checklist, like the "ABC" approach to resuscitation. This prevents anchoring bias on seemingly normal individual vital signs.

Pearl #6: Combine SI with lactate for powerful risk stratification. The combination of elevated SI and elevated lactate creates a "double jeopardy" scenario with particularly high mortality risk. Consider this combination an indication for aggressive, protocol-driven resuscitation.[20]

Future Directions and Emerging Evidence

Continuous SI monitoring using wearable devices and telemetry systems represents an exciting frontier. Rather than intermittent vital sign checks, continuous SI tracking could enable early detection of deterioration, potentially triggering automated alerts before overt decompensation occurs.[21]

Machine learning algorithms incorporating SI alongside other physiological variables show promise in predicting outcomes with superior accuracy compared to traditional scoring systems. However, these tools require extensive validation before routine implementation.[22]

The COVID-19 pandemic renewed interest in SI as a prognostic tool in viral pneumonia and ARDS, with several studies suggesting utility in predicting mechanical ventilation requirements and mortality.[23] This application merits further investigation.

Conclusion

The Shock Index exemplifies how fundamental physiological principles, when appropriately applied, can rival sophisticated monitoring technologies. Its ease of calculation, universal availability, and robust evidence base across multiple shock etiologies make it an indispensable tool for the modern intensivist.

However, SI should never be used in isolation. It represents one piece of a comprehensive clinical assessment incorporating history, physical examination, laboratory data, imaging, and invasive monitoring when appropriate. The skilled clinician integrates SI into a holistic evaluation, recognizing both its power and its limitations.

For postgraduate trainees developing their critical care expertise, mastering SI calculation and interpretation provides a foundation for understanding shock pathophysiology and hemodynamic reasoning. Make it reflexive. Calculate it frequently. Trend it serially. Question discrepancies between SI and clinical appearance. Used thoughtfully, this 55-year-old tool remains remarkably relevant in contemporary critical care practice.

Final Pearl: The best monitoring tool is the one you actually use. SI's simplicity is its strength—no calculation is required to complete it, and no patient is too unstable to have it measured. Let it be your first line of hemodynamic assessment in every critically ill patient.

References

Allgöwer M, Burri C. Shock index. Dtsch Med Wochenschr. 1967;92(43):1947-1950.
Rady MY, Nightingale P, Little RA, Edwards JD. Shock index: a re-evaluation in acute circulatory failure. Resuscitation. 1992;23(3):227-234.
Cannon CM, Braxton CC, Kling-Smith M, et al. Utility of the shock index in predicting mortality in traumatically injured patients. J Trauma. 2009;67(6):1426-1430.
Mutschler M, Nienaber U, Münzberg M, et al. The Shock Index revisited - a fast guide to transfusion requirement? A retrospective analysis on 21,853 patients derived from the TraumaRegister DGU. Crit Care. 2013;17(4):R172.
Birkhahn RH, Gaeta TJ, Terry D, et al. Shock index in diagnosing early acute hypovolemia. Am J Emerg Med. 2005;23(3):323-326.
Terceros-Almanza LJ, García-Fuentes C, Bermejo-Aznárez S, et al. Prediction of massive bleeding. Shock index and modified shock index. Med Intensiva. 2017;41(9):532-538.
Schiller AM, Howard JT, Convertino VA. The physiology of blood loss and shock: New insights from a human laboratory model of hemorrhage. Exp Biol Med. 2017;242(8):874-883.
Torabi M, Mirafzal A, Rastegari A, et al. Association of triage time Shock Index, Modified Shock Index, and Age Shock Index with mortality in Emergency Severity Index level 2 patients. Am J Emerg Med. 2016;34(1):63-68.
McNab A, Burns B, Bhullar I, et al. An analysis of shock index as a correlate for outcomes in trauma by age group. Surgery. 2013;154(2):384-387.
Vandromme MJ, Griffin RL, Kerby JD, et al. Identifying risk for massive transfusion in the relatively normotensive patient: utility of the prehospital shock index. J Trauma. 2011;70(2):384-390.
Berger T, Green J, Horeczko T, et al. Shock index and early recognition of sepsis in the emergency department: pilot study. West J Emerg Med. 2013;14(2):168-174.
Jayaprakash N, Gajic O, Frank RD, Smischney N. Elevated modified shock index in early sepsis is associated with myocardial dysfunction and mortality. J Crit Care. 2018;43:30-35.
Sam A, Sánchez D, Gómez V, et al. The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism. Eur Respir J. 2011;37(4):762-766.
Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37(5):1670-1677.
Matsushima K, Hogan AR, Hakim S, et al. Redefining the hard signs of cardiac injury: A hypothesis generating review. Am Surg. 2018;84(6):948-953.
Liu YC, Liu JH, Fang ZA, et al. Modified shock index and mortality rate of emergency patients. World J Emerg Med. 2012;3(2):114-117.
Zarzaur BL, Croce MA, Magnotti LJ, Fabian TC. Identifying life-threatening shock in the older injured patient: an analysis of the National Trauma Data Bank. J Trauma. 2010;68(5):1134-1138.
Myint PK, Sheng S, Xian Y, et al. Shock index predicts patient-related clinical outcomes in stroke. J Am Heart Assoc. 2018;7(18):e007581.
Le Bas A, Chandraharan E, Addei A, Pathak S. Use of the "obstetric shock index" as an adjunct in identifying significant maternal morbidity at cesarean section. Int J Gynaecol Obstet. 2014;124(1):56-59.
Régnier MA, Raux M, Le Manach Y, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012;117(6):1276-1288.
Convertino VA, Moulton SL, Grudic GZ, et al. Use of advanced machine-learning techniques for noninvasive monitoring of hemorrhage. J Trauma. 2011;71(1 Suppl):S25-32.
Kang L, Zhao H, Chen D, et al. Artificial intelligence algorithm improves accuracy for early detection of clinical deterioration. Am J Respir Crit Care Med. 2020;202(3):456-460.
Haimovich AD, Ravindra NG, Stoytchev S, et al. Development and validation of the quick COVID-19 severity index: a prognostic tool for early clinical decompensation. Ann Emerg Med. 2020;76(4):442-453.

Conflict of Interest: None declared.

Funding: No funding was received for this review.